RecallRadar

FDA Drug recall D-862-2014

NICOTINE POLACRILEX, LOZENGE, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00135051001

On 2014-01-29 the FDA classified a Class II recall of NICOTINE POLACRILEX, LOZENGE, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00135051001 by Aidapak Services, citing labeling: Label Mixup: NICOTINE POLACRILEX, LOZENGE, 2 mg may have potentially been mislabeled as one of the following drugs: ESTRADIOL, Tablet, 0.5 mg, NDC 00555089902, Pedigree:….

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-862-2014
ClassificationClass II
Statusterminated
Initiated2013-07-02
Published2014-01-29
Last updated2026-09-13 11:51 UTC
CompanyAidapak Services
DistributionAZ, CA, OR, WA

Product

NICOTINE POLACRILEX, LOZENGE, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00135051001.

Reason

Labeling: Label Mixup: NICOTINE POLACRILEX, LOZENGE, 2 mg may have potentially been mislabeled as one of the following drugs: ESTRADIOL, Tablet, 0.5 mg, NDC 00555089902, Pedigree: AD30993_11, EXP: 5/9/2014; ACAMPROSATE CALCIUM DR, Tablet, 333 mg, NDC 00456333001, Pedigree: W002973, EXP: 6/11/2014; CALCITRIOL, Capsule, 0.5 mcg, NDC 63304024001, Pedigree: W003730, EXP: 6/26/2014; ESZOPICLONE, T

Identifiers

code_info
NICOTINE POLACRILEX, LOZENGE, 2 mg has the following codes: Pedigree: AD32973_7, EXP: 5/9/2014; Pedigree: W002974, E…NICOTINE POLACRILEX, LOZENGE, 2 mg has the following codes: Pedigree: AD32973_7, EXP: 5/9/2014; Pedigree: W002974, EXP: 6/11/2014; Pedigree: W003749, EXP: 6/26/2014; Pedigree: W002766, EXP: 6/6/2014; Pedigree: AD21858_1, EXP: 5/1/2014; Pedigree: AD46333_10, EXP: 5/16/2014.

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-862-2014%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.